JP2016517866A - 認知症または軽度認知障害を予防または治療する組成物を製造するための安息香酸塩の使用 - Google Patents
認知症または軽度認知障害を予防または治療する組成物を製造するための安息香酸塩の使用 Download PDFInfo
- Publication number
- JP2016517866A JP2016517866A JP2016510654A JP2016510654A JP2016517866A JP 2016517866 A JP2016517866 A JP 2016517866A JP 2016510654 A JP2016510654 A JP 2016510654A JP 2016510654 A JP2016510654 A JP 2016510654A JP 2016517866 A JP2016517866 A JP 2016517866A
- Authority
- JP
- Japan
- Prior art keywords
- benzoate
- sodium benzoate
- alzheimer
- disease
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000010877 cognitive disease Diseases 0.000 title claims abstract description 34
- 208000027061 mild cognitive impairment Diseases 0.000 title claims abstract description 30
- 206010012289 Dementia Diseases 0.000 title claims abstract description 28
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 title claims abstract description 17
- 239000000203 mixture Substances 0.000 title claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 46
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical group [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 46
- 235000010234 sodium benzoate Nutrition 0.000 claims description 42
- 239000004299 sodium benzoate Substances 0.000 claims description 42
- 229940050390 benzoate Drugs 0.000 claims description 11
- 235000010237 calcium benzoate Nutrition 0.000 claims description 2
- 239000004301 calcium benzoate Substances 0.000 claims description 2
- HZQXCUSDXIKLGS-UHFFFAOYSA-L calcium;dibenzoate;trihydrate Chemical compound O.O.O.[Ca+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 HZQXCUSDXIKLGS-UHFFFAOYSA-L 0.000 claims description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 2
- 235000010235 potassium benzoate Nutrition 0.000 claims description 2
- 239000004300 potassium benzoate Substances 0.000 claims description 2
- 229940103091 potassium benzoate Drugs 0.000 claims description 2
- 150000001558 benzoic acid derivatives Chemical class 0.000 claims 2
- 230000000694 effects Effects 0.000 description 29
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 27
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 27
- 239000000902 placebo Substances 0.000 description 20
- 229940068196 placebo Drugs 0.000 description 20
- 102000004674 D-amino-acid oxidase Human genes 0.000 description 16
- 108010003989 D-amino-acid oxidase Proteins 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 13
- 230000001149 cognitive effect Effects 0.000 description 13
- 230000015654 memory Effects 0.000 description 12
- 230000006872 improvement Effects 0.000 description 10
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 9
- 229930195711 D-Serine Natural products 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 230000008449 language Effects 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 8
- 230000013016 learning Effects 0.000 description 8
- 230000007423 decrease Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 230000003936 working memory Effects 0.000 description 6
- 230000032683 aging Effects 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 210000001638 cerebellum Anatomy 0.000 description 5
- 230000019771 cognition Effects 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 210000004129 prosencephalon Anatomy 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 210000003710 cerebral cortex Anatomy 0.000 description 4
- 230000003920 cognitive function Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 230000000926 neurological effect Effects 0.000 description 4
- 230000005062 synaptic transmission Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 208000030251 communication disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- 210000001320 hippocampus Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229960004640 memantine Drugs 0.000 description 3
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 3
- 210000001178 neural stem cell Anatomy 0.000 description 3
- 230000007310 pathophysiology Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000006999 cognitive decline Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 238000010984 neurological examination Methods 0.000 description 2
- 208000023516 stroke disease Diseases 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000218628 Ginkgo Species 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 230000037410 cognitive enhancement Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000002565 electrocardiography Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000007979 neuropsychological functioning Effects 0.000 description 1
- 238000010855 neuropsychological testing Methods 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 229940053504 other anti-dementia drug in atc Drugs 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000858 peroxisomal effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960004526 piracetam Drugs 0.000 description 1
- 230000026797 positive regulation of anti-apoptosis Effects 0.000 description 1
- 230000015284 positive regulation of neurogenesis Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000002442 prefrontal cortex Anatomy 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 230000031836 visual learning Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/SG2014/000140 WO2015147742A1 (fr) | 2014-03-24 | 2014-03-24 | Utilisation d'un sel d'acide benzoïque dans la fabrication d'une composition pour prévenir ou traiter la démence ou un trouble cognitif léger |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017144263A Division JP6550426B2 (ja) | 2017-07-26 | 2017-07-26 | 認知症または軽度認知障害を予防または治療する組成物を製造するための安息香酸塩の使用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2016517866A true JP2016517866A (ja) | 2016-06-20 |
Family
ID=54196083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016510654A Pending JP2016517866A (ja) | 2014-03-24 | 2014-03-24 | 認知症または軽度認知障害を予防または治療する組成物を製造するための安息香酸塩の使用 |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JP2016517866A (fr) |
| KR (2) | KR20160029837A (fr) |
| AU (1) | AU2014386718B8 (fr) |
| CA (1) | CA2902498C (fr) |
| DE (1) | DE212014000063U1 (fr) |
| SG (1) | SG11201507188QA (fr) |
| WO (1) | WO2015147742A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11008277B2 (en) * | 2016-06-13 | 2021-05-18 | Syneurx International (Taiwan) Corp. | Co-crystals of sodium benzoate and uses thereof |
| CN109563024B (zh) | 2016-06-13 | 2023-06-06 | 心悦生医股份有限公司 | 苯甲酸锂的共晶及其用途 |
| US11369579B2 (en) | 2016-10-24 | 2022-06-28 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| US10336679B2 (en) * | 2016-10-24 | 2019-07-02 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| JP6940631B2 (ja) * | 2017-03-03 | 2021-09-29 | 科進製藥科技股▲分▼有限公司Ｅｘｃｅｌｓｉｏｒ Ｐｈａｒｍａｔｅｃｈ Ｌａｂｓ | 安息香酸塩で自閉症スペクトラム障害を予防または治療するための方法 |
| KR20230047509A (ko) * | 2017-11-22 | 2023-04-07 | 치에-신 린 | 우울증의 예방 또는 치료용 벤조익산 또는 이의 염 및 유도체 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007534657A (ja) * | 2003-12-29 | 2007-11-29 | セプラコア インコーポレーテッド | ベンゾ［ｄ］イソオキサゾール阻害剤 |
| JP2012515720A (ja) * | 2009-01-20 | 2012-07-12 | ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター | 向精神薬の働きを向上させるソルビン酸、安息香酸及びその誘導体 |
| WO2013004996A1 (fr) * | 2011-07-07 | 2013-01-10 | Takeda Pharmaceutical Company Limited | 3-hydroxy-2(1h)-pyridinones 5- ou 6- substituées utilisées en tant qu'inhibiteurs de d-acide aminé oxydase (daao) en thérapie de maladies telles que la schizophrénie, un trouble cognitif et la douleur |
| WO2013073577A1 (fr) * | 2011-11-15 | 2013-05-23 | アステラス製薬株式会社 | Composé hétérocyclique aromatique dihydroxy |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601915D0 (en) * | 1986-01-27 | 1986-03-05 | Efamol Ltd | Pharmaceutical compositions |
-
2014
- 2014-03-24 AU AU2014386718A patent/AU2014386718B8/en active Active
- 2014-03-24 SG SG11201507188QA patent/SG11201507188QA/en unknown
- 2014-03-24 CA CA2902498A patent/CA2902498C/fr active Active
- 2014-03-24 KR KR1020167003184A patent/KR20160029837A/ko not_active Application Discontinuation
- 2014-03-24 DE DE212014000063.7U patent/DE212014000063U1/de not_active Expired - Lifetime
- 2014-03-24 WO PCT/SG2014/000140 patent/WO2015147742A1/fr active Application Filing
- 2014-03-24 KR KR1020177024853A patent/KR102162073B1/ko active IP Right Grant
- 2014-03-24 JP JP2016510654A patent/JP2016517866A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007534657A (ja) * | 2003-12-29 | 2007-11-29 | セプラコア インコーポレーテッド | ベンゾ［ｄ］イソオキサゾール阻害剤 |
| JP2012515720A (ja) * | 2009-01-20 | 2012-07-12 | ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター | 向精神薬の働きを向上させるソルビン酸、安息香酸及びその誘導体 |
| WO2013004996A1 (fr) * | 2011-07-07 | 2013-01-10 | Takeda Pharmaceutical Company Limited | 3-hydroxy-2(1h)-pyridinones 5- ou 6- substituées utilisées en tant qu'inhibiteurs de d-acide aminé oxydase (daao) en thérapie de maladies telles que la schizophrénie, un trouble cognitif et la douleur |
| WO2013073577A1 (fr) * | 2011-11-15 | 2013-05-23 | アステラス製薬株式会社 | Composé hétérocyclique aromatique dihydroxy |
Non-Patent Citations (1)
| Title |
|---|
| メルクマニュアル, vol. 第１８版, JPN6017010096, 2006, pages 1924 - 1931, ISSN: 0003523958 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014386718A8 (en) | 2017-12-07 |
| WO2015147742A1 (fr) | 2015-10-01 |
| DE212014000063U1 (de) | 2015-10-12 |
| AU2014386718A1 (en) | 2015-10-08 |
| AU2014386718B8 (en) | 2017-12-07 |
| AU2014386718B2 (en) | 2017-07-20 |
| CA2902498A1 (fr) | 2015-09-24 |
| CA2902498C (fr) | 2017-03-28 |
| SG11201507188QA (en) | 2015-10-29 |
| KR102162073B1 (ko) | 2020-10-07 |
| CA2902498F (fr) | 2015-09-24 |
| KR20160029837A (ko) | 2016-03-15 |
| KR20170104658A (ko) | 2017-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lin et al. | Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial | |
| Joe et al. | Cognitive symptoms of Alzheimer’s disease: clinical management and prevention | |
| Pawełczyk et al. | A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia | |
| Bhandari et al. | Resveratrol suppresses neuroinflammation in the experimental paradigm of autism spectrum disorders | |
| Moreno | Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial | |
| Farlow et al. | Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study | |
| Mix et al. | A double‐blind, placebo‐controlled, randomized trial of Ginkgo biloba extract EGb 761® in a sample of cognitively intact older adults: neuropsychological findings | |
| AU2014386718B2 (en) | Use of benzoic acid salt in the manufactue of a composition for preventing or treating dementia or mild cognitive impairment | |
| Moretti et al. | Depression and Alzheimer's disease: symptom or comorbidity? | |
| JP6608858B2 (ja) | 疲労を減少させるためまたは予防するためおよび認知機能を改善するためのｌ−カルニチン、その塩および誘導体の使用 | |
| JP2019529411A (ja) | 不安症およびうつ病の治療のためのプリドピジンの使用 | |
| JP6550426B2 (ja) | 認知症または軽度認知障害を予防または治療する組成物を製造するための安息香酸塩の使用 | |
| Bhattacharya et al. | Attention enhancing effects of methylphenidate are age-dependent | |
| TWI573588B (zh) | 苯甲酸鹽用於製備治療失智症或輕度認知障礙之醫藥組成物的用途 | |
| JP2008542263A (ja) | 認知能力改善薬 | |
| Pallanti et al. | Social anxiety and premorbid personality disorders in paranoid schizophrenic patients treated with clozapine | |
| Mintzer | The search for better noncholinergic treatment options for Alzheimer's disease | |
| US20170216234A1 (en) | Benzoates for use in treating dementia | |
| Hashemian et al. | A comparison of the effects of reboxetine and placebo on reaction time in adults with Attention Deficit-Hyperactivity Disorder (ADHD) | |
| Gilleen | Cognitive enhancement in schizophrenia | |
| Román | Therapeutic strategies for vascular dementia | |
| JP2024524679A (ja) | アルツハイマー病の処置方法 | |
| Steyn | The effect of early–life exposure of stress–sensitive rats to the serotonin–norepinephrine reuptake inhibitor vanlafaxine on behaviour in adulthood | |
| Vale et al. | Treatment of Alzheimer's disease in Brazil: I. Cognitive disorders | |
| WO2024050323A1 (fr) | Ulotaront pour le traitement adjuvant d'un trouble dépressif majeur |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160406 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160801 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161024 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170327 |